Black Diamond Therapeutics, Inc. - 8-K Filing
Black Diamond Therapeutics announced positive Phase 2 results for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations. Preliminary median progression-free survival was 15.2 months, CNS objective response rate remained at 86%, and no new safety signals were observed. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $BDTX